Compare Quest Diagnostics Inc (DGX) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs IAC/Interactivecorp — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while IAC/Interactivecorp trades at $40.88 (market cap $3.05B). The key difference: Quest Diagnostics Inc is far larger — about 8.4× IAC/Interactivecorp's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and IAC/Interactivecorp for 79 Days on average.
| DGX | PPLI | |
|---|---|---|
Market Cap | $25.48B | $3.05B |
Volume | 941,866 | 931,019 |
Sector | Health | Media |
52-Week High | $247.45 | $47.62 |
52-Week Low | $173.49 | $31.52 |
Typical Hold Time | 56 Days | 79 Days |
Enterprise Value | $31.23B | $3.53B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
PPLI trades at $40.89, up 0.74% with strong analyst support (71% buy ratings) amid MGM acquisition speculation. The stock shows bullish technical momentum with recent earnings volatility - missing Q4 2025 and Q1 2026 but beating Q2 2026 expectations. Revenue declined to $2.39B in 2025 while maintaining healthy gross margins of 66.35%. The company's valuation appears attractive with P/E of 6.92 and P/B of 0.6, though negative cash flow of -$820M in 2025 raises concerns.
The outlook remains positive given potential MGM bid and improving 2026 profit projections (14.12% margin). Key risks include volatile earnings, declining revenue trends, and negative cash flow. With strong institutional support and takeover speculation, the stock offers upside potential but requires monitoring of operational turnaround and acquisition developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
